Mij lukt het alleszins :-)
Hier dan maar weer wat parels voor de zwijnen...
Next sheet, sheet number 10, an update on Quinvaxem. During the third quarter, Crucell was awarded a portion of $300 million worth of sale for Quinvaxem out of a tender for pentavalent vaccine. The tender is for the next three years, so for the period 2010-2012 and brings our total award for Quinvaxem to about $800 million. We expect additional awards in the upcoming period and possibly already in 2010. Only half of the original tender volume's been awarded by the supranational organization at this time and secondly to date Crucell has supplied over 130 million doses of Quinvaxem which is significantly more than any of the Europe manufacturers of pentavalent vaccine.
Crucell's track record with regard to all time delivery and product quality and consistency is both well known and recognized by the supranational organizations as well as by many local authorities. Our existing plant in Korea use line speeds and output levels that are truly best in class. Our colleagues in Korea have won a number of prestigious awards from the Korean government during 2009 and their contribution to our 2009 results been significant, but also the new site project is progressing very well. In a record 13 months, we went from groundbreaking to commissioning and with commissioning we mean that all equipments now been installed in the facility, all connections have been made, piping, cabling, air handling and [lot] and 13 months is a fantastic achievements taking into account that this is not a small factory. To remind you the footprint of the factory has the size of two soccer fields.
To get such a milestone in most western countries would have taken at least twice as long. We now enter the phase of commissioning and validation and that will take most of 2010.
So in summary looking at Quinvaxem, whilst all our producers have now been pre-qualified, we feel confident on our ability to supply additional volumes when requested to do so and in the future, we will benefit from improved efficiencies, output and renewed tax benefits.